175 results about "Pathogenic Escherichia coli" patented technology

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.

The present invention relates to a method for the detection of pathogenic E. coli in a sample comprising PCR amplification of DNA isolated from said sample using oligonucleotide primers specific for pathogenic E. coli.

The invention discloses application of recombinant escherichia coli with overexpression of a fimH gene in the fermentation production of amino acid. According to the invention, by drawing lessons fromthe medical experience that compared with free cells, cells of a biological membrane formed by pathogenic escherichia coli are more adaptable to extreme environments, the formation of an escherichiacoli biological membrane can be regulated and controlled by the fimH gene regulated and controlled by a known fim operon, the change of an amino acid metabolic pathway after overexpression of the fimHgene is discovered through transcriptome analysis, groundwork is laid for screening recombination strains of other high-yield amino acid organic acid in a industrialization process in a later period,and the goal of increasing the yield, the fermentation rate and the sugar conversion rate is finally achieved.

The present invention relates to novel genes located in two chromosomal regions within uropathogenic E. coli that are associated with virulence. These chromosomal regions are known as pathogenicity islands (PAIs). In particular, the present application discloses 142 sequenced fragments (contigs) of DNA from two pools of cosmids covering pathogenicity islands PAI IV and PAI V located on the chromosome of the uropathogenic Escherichia coli J96. Further disclosed are 351 predicted protein-coding open reading frames within the sequenced fragments.

The invention provides a multiplex PCR (Polymerase Chain Reaction) primer group for avian pathogenic escherichia coli, pasteurella multocida, proteus mirabilis, pseudomonas aeruginosa, salmonella andstaphylococcus aureus, a multiplex PCR detection kit comprising the primer group, and a multiplex PCR detection method using the primer group. The primer group comprises primer pairs PhoA-F and PhoA-Rfor specifically amplifying a gene phoA of the avian escherichia coli, primer pairs KMT-F and KMT-R for specifically amplifying a gene KMT1 of the pasteurella multocida, primer pairs AtpD-F and AtpD-R for specifically amplifying a gene AtpD of the proteus mirabilis, primer pairs PETA-F and PETA-R for specifically amplifying a gene PETA of the pseudomonas aeruginosa, primer pairs InvA-F and InvA-Rfor specifically amplifying a gene InvA of the salmonella, and prier pairs NuC-F and NuC-R for specifically amplifying a gene nuc of the staphylococcus aureus.

The invention discloses an escherichia coli bacteriophage vBE_coM_swi3 with a preservation number of CCTCC NO: M2019467. The bacteriophage belongs to myoviridae and has a polyhedral head and a telescopic tail structure, the diameter of the head is about 80 nm, and the length of the tail is about 120 nm; transparent empty spots can be formed on a solid culture medium, no halo ring exists around thesolid culture medium, the edge is clear and regular, and the diameter is about 1-1.5 mm; the bacteriophage has a good cracking effect on swine-derived and chicken-derived escherichia coli in a breeding environment, particularly on swine-derived and chicken-derived pathogenic escherichia coli, and has very wide application prospects in multiple aspects of pharmaceutical preparations, feed additives and the like for preventing and treating swine colibacillosis and chicken colibacillosis.

The invention provides a traditional Chinese medicine composition for treating porcine pathogenic Escherichia coli diseases. The raw material medicines comprise common andrographis herb, scutellaria baicalensis, white paeony root, cacumen biotae, hempleaf negundo chastetree leaf, the root of Chinese pulsatilla, codonopsis pilosula, radix bupleuri, madder, smoked plum, centipeda minima, hawthorn, pericarpium citri reticulatae, rhizoma polygonati, rhizoma kaempferiae, honeysuckle stem, rhizoma galangae, adenophora tetraphylla, gorgon fruit, corydalis tuber, folium ginkgo, fringed pink and semen raphani. The traditional Chinese medicine composition provided in the invention has the advantages of bacteria resistance, virus resistance, small side effects, zero residue and no drug resistance, is a good substitute of antibiotics and has a wide development prospect in the aspect of treating the porcine pathogenic Escherichia coli diseases.

The invention relates to the field of microecological feed additives, and particularly relates to preparation and application of a composite microecological feed additive. The composite microecological feed additive provided by the invention is prepared from screened active compound probiotics. Diarrhea caused by domestic animal bacterial infections can be prevented and treated. Two probiotics used by the composite microecological feed additive have the abilities of inhibiting infection of common gastrointestinal pathogens of animals, including shigella dysenteriae, pathogenic escherichia coli and salmonella enteritidis, and also can reduce the toxicity caused by dysentery bacillus infection Caco-2 cells and inhibit adhesion of the shigella dysenteriae to the Caco-2 cells. Finally, the obvious effects of stimulating the animal immunity, improving the gastrointestinal digestion abilities of animals, and promoting animal growth are achieved. A production technology of a strain adopts a liquid fermental cultivation technology and a low-temperature freeze drying technology, so that the obtained inoculant is high in survival rate and purity. The composite microecological feed additive is a green environment-friendly feed additive.

The invention belongs to the technical field of biology and relates to a preparation method and application of a novel antimicrobial peptide Misgurin mutant. The technical scheme is as follows: introducing glutamine at the C tail end of the amino acid sequence of natural Misgurin so as to design a novel Misgurin mutant; selecting Pichia yeast biased codons so as to artificially synthesize a complete gene of the novel Misgurin mutant; constructing a Pichia yeast secretion type expression vector pPICZaA-M; transforming a host cell SMD1168 by a vector electroporation method; selecting to obtain high-efficiency expression strains; and under proper culture conditions, ensuring 100 microgram of recombinant novel Misgurin mutant is contained in per milliliter of expression supernatant. The obtained product has a good nematocidal activity on staphylococcus aureus, pig salmonella and pig pathogenic Escherichia coli K88, K99 and 987P, and has an obvious effect on prevention and treatment of clinical bacterial diseases.

The present invention relates to a Myoviridae bacteriophage Esc-CHP-2 that is isolated from the nature and can kill specifically enteropathogenic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12661BP), and a method for preventing and treating the infections of enteropathogenic E. coli using the composition comprising said bacteriophage as an active ingredient.